Syndax Pharmaceuticals (SNDX) Debt to Equity (2020 - 2024)
Syndax Pharmaceuticals (SNDX) has disclosed Debt to Equity for 5 consecutive years, with $1.19 as the latest value for Q4 2024.
- For Q4 2024, Debt to Equity changed N/A year-over-year to $1.19; the TTM value through Dec 2024 reached $1.19, changed N/A, while the annual FY2024 figure was $1.19, N/A changed from the prior year.
- Debt to Equity hit $1.19 in Q4 2024 for Syndax Pharmaceuticals, up from $0.06 in the prior quarter.
- Across five years, Debt to Equity topped out at $1.19 in Q4 2024 and bottomed at $0.05 in Q4 2021.
- Average Debt to Equity over 4 years is $0.22, with a median of $0.09 recorded in 2021.
- On a YoY basis, Debt to Equity climbed as much as 29.61% in 2021 and fell as far as 76.03% in 2021.
- Syndax Pharmaceuticals' Debt to Equity stood at $0.08 in 2020, then tumbled by 38.36% to $0.05 in 2021, then rose by 13.52% to $0.06 in 2022, then soared by 2036.64% to $1.19 in 2024.
- According to Business Quant data, Debt to Equity over the past three periods came in at $1.19, $0.06, and $0.05 for Q4 2024, Q2 2022, and Q1 2022 respectively.